Skip to content

Commit

Permalink
fixing snaps
Browse files Browse the repository at this point in the history
  • Loading branch information
@Melkiades
Melkiades committed Jul 10, 2024
1 parent 8520711 commit b81170a
Show file tree
Hide file tree
Showing 6 changed files with 70 additions and 69 deletions.
32 changes: 16 additions & 16 deletions package/tests/testthat/_snaps/stable/tables-ADA-adat01.md
View file
Original file line number Diff line number Diff line change
Expand Up @@ -5,22 +5,22 @@
Output
Baseline Prevalence and Incidence of Treatment Emergent ADA
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of ADAs
Baseline evaluable patients 134 132 0 0 266
Patient with a positive sample at baseline 63 (47.0%) 64 (48.5%) 0 0 127 (47.7%)
Patient with no positive samples at baseline 71 68 0 0 139
Incidence of Treatment Emergent ADAs
Post-baseline evaluable patients 134 132 0 0 266
Patient positive for Treatment Emergent ADA 0 0 0 0 0
Treatment-induced ADA 0 0 0 0 0
Treatment-enhanced ADA 0 0 0 0 0
Patient negative for Treatment Emergent ADA 0 0 0 0 0
Treatment unaffected 0 0 0 0 0
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of ADAs
Baseline evaluable patients 134 132 0 0 266
Patient with a positive sample at baseline 63 (47.0%) 64 (48.5%) 0 0 127 (47.7%)
Patient with no positive samples at baseline 71 68 0 0 139
Incidence of Treatment Emergent ADAs
Post-baseline evaluable patients 134 132 0 0 266
Patient positive for Treatment Emergent ADA 0 0 0 0 0
Treatment-induced ADA 0 0 0 0 0
Treatment-enhanced ADA 0 0 0 0 0
Patient negative for Treatment Emergent ADA 0 0 0 0 0
Treatment unaffected 0 0 0 0 0
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————
ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient = a patient with an ADA assay result from a baseline sample(s)
Post-baseline evaluable patient = a patient with an ADA assay result from at least one post-baseline sample Number of patients positive for Treatment Emergent
Expand Down
36 changes: 18 additions & 18 deletions package/tests/testthat/_snaps/stable/tables-ADA-adat04a.md
View file
Original file line number Diff line number Diff line change
Expand Up @@ -6,24 +6,24 @@
Baseline Prevalence and Incidence of Treatment Emergent NAbs
Protocol: A: Drug X Antibody
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of NAbs
Baseline evaluable patients for ADA 134 132 0 0 266
Patients with a positive ADA sample at baseline 63 64 0 0 127
Patients with a positive NAb sample at baseline 0 0 0 0 0
Patient with no positive NAb samples at baseline 0 0 0 0 0
Incidence of Treatment Emergent NAbs
Post-baseline evaluable patients for ADA 134 132 0 0 266
Patients positive for ADA 66 59 0 0 125
Patients positive for Treatment Emergent NAb 0 0 0 0 0
Treatment-induced NAb 0 0 0 0 0
Treatment-enhanced NAb 0 0 0 0 0
Patients negative for NAb 0 0 0 0 0
Treatment unaffected 0 0 0 0 0
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of NAbs
Baseline evaluable patients for ADA 134 132 0 0 266
Patients with a positive ADA sample at baseline 63 64 0 0 127
Patients with a positive NAb sample at baseline 0 0 0 0 0
Patient with no positive NAb samples at baseline 0 0 0 0 0
Incidence of Treatment Emergent NAbs
Post-baseline evaluable patients for ADA 134 132 0 0 266
Patients positive for ADA 66 59 0 0 125
Patients positive for Treatment Emergent NAb 0 0 0 0 0
Treatment-induced NAb 0 0 0 0 0
Treatment-enhanced NAb 0 0 0 0 0
Patients negative for NAb 0 0 0 0 0
Treatment unaffected 0 0 0 0 0
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s)
Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s)
Expand Down
30 changes: 15 additions & 15 deletions package/tests/testthat/_snaps/stable/tables-ADA-adat04b.md
View file
Original file line number Diff line number Diff line change
Expand Up @@ -6,21 +6,21 @@
Baseline Prevalence and Incidence of Neutralizing Antibodies (NAbs)
Protocol: A: Drug X Antibody
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of NAbs
Baseline evaluable patients for ADA 134 132 0 0 266
Patients with a positive ADA sample at baseline 63 64 0 0 127
Patients with a positive NAb sample at baseline 0 0 0 0 0
Patients with no positive NAb sample at baseline 0 0 0 0 0
Incidence of NAbs
Post-baseline evaluable patients for ADA 134 132 0 0 266
Patients positive for ADA 66 59 0 0 125
Patients positive for NAb 0 0 0 0 0
Patients negative for NAb 134 132 0 0 266
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X C: Combination <Missing> B: Placebo All Drug X
(N=134) (N=132) (N=0) (N=134) (N=266)
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline Prevalence of NAbs
Baseline evaluable patients for ADA 134 132 0 0 266
Patients with a positive ADA sample at baseline 63 64 0 0 127
Patients with a positive NAb sample at baseline 0 0 0 0 0
Patients with no positive NAb sample at baseline 0 0 0 0 0
Incidence of NAbs
Post-baseline evaluable patients for ADA 134 132 0 0 266
Patients positive for ADA 66 59 0 0 125
Patients positive for NAb 0 0 0 0 0
Patients negative for NAb 134 132 0 0 266
—————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s) Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s) Post-baseline evaluable patient for ADA = a patient with an ADA assay result from at least one post-baseline sample Post-baseline evaluable patient for NAb = a patient with a NAb assay result from at least one post-baseline sample Number of patients positive for ADA = the number of post-baseline evaluable patients for ADA determined to have Treatment Emergent ADA during the study period.
Number of patients positive for NAb = the number (and percentage) of post-baseline evaluable patients for ADA determined to have at least one positive post-baseline NAb result during the study period. Number of patients negative for NAb = number of post-baseline evaluable patients with all negative post-baseline NAb results.
Expand Down
Loading

0 comments on commit b81170a

Please sign in to comment.